Overview of Sales, Earnings and Financial Position
Dr. Marijn E. Dekkers to be new Bayer CEO
Bayer Links
Investor Relations
New CEO of Bayer from October 1, 2010
Dr. Marijn E. Dekkers to be new Bayer CEO
Bayer Supervisory Board decided on company’s future management line-up
  Zoom image
|
| Dr. Marijn E. Dekkers, new Chairman of the Board of Management of Bayer AG effective October 1, 2010. |
Dekkers will join the Bayer Board of Management on January 1, 2010. He will also serve for a transitional period as CEO of Bayer HealthCare in succession to Arthur J. Higgins (53), who will leave the company during the first half of 2010 for personal reasons. Higgins was appointed Chairman of the Bayer HealthCare Executive Committee on July 1, 2004, and has served as Chairman of the Board of Management of Bayer HealthCare AG since January 1, 2006.
Following the Annual Stockholders’ Meeting on April 30, 2010, Chief Financial Officer Klaus Kühn will take retirement at the age of 58 at his own request. The Supervisory Board has appointed Werner Baumann (47), currently a member of the Board of Management of Bayer HealthCare AG and of this subgroup’s Executive Committee, to succeed him. Baumann will also join the Bayer AG Board of Management effective January 1, 2010. Baumann’s successor will be Manfred Vehreschild, currently Head of Biltrolling at Bayer AG.
 Zoom image
|
| Werner Wenning, Chairman of the Board of Management of Bayer AG. |
Thomas de Win, Chairman of the Central Works Council of Bayer AG and Vice Chairman of the Supervisory Board, also expressed his satisfaction with the succession procedure. “A structured transition has been ensured by extending Mr. Wenning’s contract of service. From the employees’ point of view, we would have welcomed a longer extension as Mr. Wenning has worked closely with employee representatives over the past years to implement tremendous changes successfully and in a socially responsible manner. Following my first meeting with his successor, I am very confident that Dr. Dekkers will continue this proven approach. Bayer’s employees will support him to the best of their ability.”
Commenting on the retirement of CFO Klaus Kühn, Supervisory Board Chairman Schneider said: “We greatly regret the departure of Klaus Kühn, who is a highly competent and respected CFO. However, we respect his decision to pursue a new route in life.”
Arthur J. Higgins is also leaving Bayer at his own request. “Over the past five years, Mr. Higgins has played a key role in realigning and strengthening our health care business. For this he deserves our thanks and appreciation,” said Werner Wenning.
Arthur J. Higgins is also leaving Bayer at his own request. “Over the past five years, Mr. Higgins has played a key role in realigning and strengthening our health care business. For this he deserves our thanks and appreciation,” said Werner Wenning.
Dr. Marijn E. Dekkers
In Dekkers, who holds both Dutch and U.S. citizenship, Bayer is gaining a highly experienced international manager as its new CEO.
Born on September 22, 1957 in the Dutch city of Tilburg, Dekkers studied chemistry at the universities of Nijmegen and Eindhoven after graduating from high school. As his father was the general manager of a large textile company, he recognized at an early stage the significance of international experience in career progression.
Born on September 22, 1957 in the Dutch city of Tilburg, Dekkers studied chemistry at the universities of Nijmegen and Eindhoven after graduating from high school. As his father was the general manager of a large textile company, he recognized at an early stage the significance of international experience in career progression.
After completing his education and gaining a Ph.D., the future Bayer CEO moved to the United States in 1985, starting his career in research at General Electric in Schenectady, New York. At that time, this company’s R&D center employed 2,000 scientists and was one of the oldest and most respected research facilities in North America. Dekkers originally planned this position only as a way station en route to a university professorship. However, he enjoyed working in industry so much that he stayed.
Two years later, he returned to the Netherlands to work at the GE Plastics research facility in Bergen op Zoom. When the post of his former U.S. supervisor became vacant in 1988, he returned to head polymer materials research in the United States. During this time he was elected “Technologist of the Year” at GE Plastics and contributed to 30 patents.
Dr. Dekkers held management positions in various other polymers units at GE before moving to Allied Signal (subsequently Honeywell International Inc.) in 1995. For four years he subsequently headed this company’s Specialty Films and Fluorine Chemicals business groups based in Morristown, New Jersey, moving in 1999 to head Electronic Materials in San José in California’s Silicon Valley. This business group manufactures electronic components, supplying companies such as Intel and Cisco.
In 2000, Marijn Dekkers was offered the position of Chief Operating Officer with Boston-based Thermo Electron Corporation, one of the world’s leading specialists in the manufacture of laboratory instruments such as chromatographs and mass spectrometers. The offer included the prospect of becoming the company’s CEO at a later date – and thus began a nine-year success story. Within a short time, Dekkers implemented a complete corporate reorganization. When he became President and CEO as planned in 2002, the company had a workforce of 11,000 and sales of US$ 2.2 billion.
The new CEO initiated extensive restructuring measures, divesting various units and strengthening the company’s core business through selective acquisitions, including the purchase in 2006 of the significantly larger laboratory consumables supplier Fisher Scientific. Dekkers thereby created a company which now employs 35,000 people in six business groups and generates annual sales of US$ 10.5 billion.
Two years ago, Marijn Dekkers was also elected to the Board of Directors of Biogen Idec, one of the world’s leading biotechnology companies. Based in Cambridge, Massachusetts, Biogen has branches in 27 countries.
Dr. Dekkers is married to an American and has three daughters. As a student, he was one of the best tennis players in the Netherlands, playing on a semi-professional basis in Germany’s top league for a number of years.
Two years later, he returned to the Netherlands to work at the GE Plastics research facility in Bergen op Zoom. When the post of his former U.S. supervisor became vacant in 1988, he returned to head polymer materials research in the United States. During this time he was elected “Technologist of the Year” at GE Plastics and contributed to 30 patents.
Dr. Dekkers held management positions in various other polymers units at GE before moving to Allied Signal (subsequently Honeywell International Inc.) in 1995. For four years he subsequently headed this company’s Specialty Films and Fluorine Chemicals business groups based in Morristown, New Jersey, moving in 1999 to head Electronic Materials in San José in California’s Silicon Valley. This business group manufactures electronic components, supplying companies such as Intel and Cisco.
In 2000, Marijn Dekkers was offered the position of Chief Operating Officer with Boston-based Thermo Electron Corporation, one of the world’s leading specialists in the manufacture of laboratory instruments such as chromatographs and mass spectrometers. The offer included the prospect of becoming the company’s CEO at a later date – and thus began a nine-year success story. Within a short time, Dekkers implemented a complete corporate reorganization. When he became President and CEO as planned in 2002, the company had a workforce of 11,000 and sales of US$ 2.2 billion.
The new CEO initiated extensive restructuring measures, divesting various units and strengthening the company’s core business through selective acquisitions, including the purchase in 2006 of the significantly larger laboratory consumables supplier Fisher Scientific. Dekkers thereby created a company which now employs 35,000 people in six business groups and generates annual sales of US$ 10.5 billion.
Two years ago, Marijn Dekkers was also elected to the Board of Directors of Biogen Idec, one of the world’s leading biotechnology companies. Based in Cambridge, Massachusetts, Biogen has branches in 27 countries.
Dr. Dekkers is married to an American and has three daughters. As a student, he was one of the best tennis players in the Netherlands, playing on a semi-professional basis in Germany’s top league for a number of years.
Werner Baumann
 Zoom image
|
| Werner Baumann, new Chief Financial Officer effective April 30, 2010. |
A year later, Baumann moved to Bayer Corporation in Tarrytown, New York, where he was latterly Head of Business Planning & Administration in the Diagnostics Business Group.
Baumann returned to Germany in July 2002 to become a member of the Board of Management of the Bayer HealthCare subgroup, which had just been formed. He is presently a member of this company’s Executive Committee and Head of Central Administration & Organization. As a member of the Board of Management of Bayer Schering Pharma until 2009, he actively participated in this company’s integration. Baumann is married and has four children.
Bookmark this page
E-mail this page
Advanced Search
